If you are on the fence about trying this GLP-1 pill do yourself a favor and try it
Authoritative Sources Use peer-reviewed and official sources to separate research context from personal instructions
After excluding individuals with pre-existing neurodegenerative or cerebrovascular disease, the study compared 30,430 patients using GLP-1RA therapy (semaglutide or tirzepatide) with 30,430 patients prescribed other antidiabetic agentsincluding biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium-glucose cotransporter 2 inhibitorsusing propensity score matching to control for baseline differences
There are several possibilities: First, if you've reached your maintenance dose but aren't tolerating it well, your provider might reduce your dose
This has raised questions about potential conflicts of interest and highlights the importance of independent research
Improving your skin and overall health should be an utmost priority
